Tularemia
ICD-10 A21 · ICD-11 1B94

Tularemia Treatment in Sepsis: Hemodynamic Instability and End-Organ Dysfunction

Clinical Scenario

This protocol covers Tularemia presenting with hemodynamic instability, end-organ dysfunction, need for respiratory support, or other signs of sepsis or severe illness — a critical subset requiring specific antimicrobial management beyond standard approaches.

Why Sepsis Changes Management

Tularemia complicated by sepsis, circulatory compromise, or organ involvement warrants a treatment strategy informed by the most robust available clinical evidence. The presence of these severity markers directly shapes which antimicrobial approach is prioritised.

Treatment Overview (Partial)

For this presentation, initial therapy centres on an aminoglycoside-based approach, favoured by clinical experience with severe disease. In selected cases, combination therapy drawing on two distinct antimicrobial classes may be considered — the complete protocol, including all options and decision points, is available via the link below.

Instant Access to Structured Evidence-Based Regimens
References

For patients with severe infection, indicated by hemodynamic instability, end-organ dysfunction, need for respiratory support, or other signs of sepsis or severe illness, health care providers should consider treating initially with an aminoglycoside if possible because of the more robust clinical experience and published evidence of aminoglycoside use for severe disease.

Health care providers also can consider prescribing combination therapy with two classes of effective antimicrobials (e.g., gentamicin plus ciprofloxacin or gentamicin plus doxycycline).

View source ↗